Compass Pathways to Announce Third Quarter Financial Results on October 31, 2024
Compass Pathways (NASDAQ: CMPS), a mental health biotechnology company, announced it will release its third quarter 2024 financial results on October 31, 2024. The company will host a conference call at 8:00 am ET (12:00 pm UK) to discuss financial results and provide business updates. A live webcast will be available on the company's website and archived for 30 days.
Compass Pathways (NASDAQ: CMPS), un'azienda biotecnologica nel campo della salute mentale, ha annunciato che pubblicherà i suoi risultati finanziari del terzo trimestre 2024 il 31 ottobre 2024. L'azienda ospiterà una conference call alle 8:00 ET (12:00 UK) per discutere i risultati finanziari e fornire aggiornamenti sull'attività. Sarà disponibile un webcast dal vivo sul sito web dell'azienda, che sarà archiviato per 30 giorni.
Compass Pathways (NASDAQ: CMPS), una empresa biotecnológica de salud mental, anunció que publicará sus resultados financieros del tercer trimestre de 2024 el 31 de octubre de 2024. La empresa llevará a cabo una llamada de conferencia a las 8:00 a.m. ET (12:00 p.m. UK) para discutir los resultados financieros y proporcionar actualizaciones comerciales. Habrá una transmisión en vivo disponible en el sitio web de la empresa y se archivará durante 30 días.
Compass Pathways (NASDAQ: CMPS)는 정신 건강 생명공학 회사로, 2024년 3분기 재무 결과를 2024년 10월 31일에 발표할 예정이라고 발표했습니다. 회사는 동부 표준시 기준 오전 8시(영국 오전 12시)에 재무 결과를 논의하고 비즈니스 업데이트를 제공하는 컨퍼런스 콜을 개최합니다. 회사 웹사이트에서 실시간 웹캐스트가 제공되며 30일 동안 아카이브됩니다.
Compass Pathways (NASDAQ: CMPS), une entreprise biotechnologique spécialisée dans la santé mentale, a annoncé qu'elle publiera ses résultats financiers pour le troisième trimestre 2024 le 31 octobre 2024. L'entreprise animera une conférence téléphonique à 8h00 ET (12h00 UK) pour discuter des résultats financiers et fournir des mises à jour commerciales. Un webinaire en direct sera disponible sur le site Web de l'entreprise et sera archivé pendant 30 jours.
Compass Pathways (NASDAQ: CMPS), ein biopharmazeutisches Unternehmen im Bereich der psychischen Gesundheit, hat bekannt gegeben, dass es seine Finanzergebnisse für das dritte Quartal 2024 am 31. Oktober 2024 veröffentlichen wird. Das Unternehmen wird um 8:00 Uhr ET (12:00 Uhr UK) eine Telefonkonferenz abhalten, um die Finanzergebnisse zu erörtern und Geschäftsinformationen bereitzustellen. Ein Live-Webcast wird auf der Unternehmenswebsite verfügbar sein und für 30 Tage archiviert.
- None.
- None.
The management team will host a conference call at 8:00 am ET (12:00 pm
A live webcast of the call will be available on the Compass Pathways website at: Third Quarter 2024 Financial Results
The webcast will also be available on the Investors section of the Compass Pathways website. The webcast will be archived for 30 days.
About Compass Pathways
Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are living with mental health challenges and who are not helped by existing standards of care. We are pioneering the development of a new model of psilocybin treatment, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has Breakthrough Therapy designation from the US Food and Drug Administration (FDA) and has received Innovative Licensing and Access Pathway (ILAP) designation in the
We have commenced a phase 3 clinical program of COMP360 psilocybin treatment in TRD, the largest randomized, controlled, double-blind psilocybin treatment clinical program ever conducted. Previously, we completed a phase 2b study with top line data showing a statistically significant (p<0.001) and clinically relevant improvement in depressive symptom severity after three weeks for patients who received a single 25mg dose of COMP360 psilocybin with psychological support. We have completed an open label phase 2 study of COMP360 psilocybin treatment for post-traumatic stress disorder (PTSD), and we are currently conducting a phase 2 clinical study in anorexia nervosa.
Compass is headquartered in
Availability of other information about Compass Pathways
Investors and others should note that we communicate with our investors and the public using our website (www.compasspathways.com), our investor relations website (ir.compasspathways.com), and on social media (LinkedIn), including but not limited to investor presentations and investor fact sheets, US Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that we post on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in us to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include additional social media channels. The contents of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241024060255/en/
Enquiries
Media: Sally Bain, sally.bain@compasspathways.com, + 1 781 458 0443
Investors: Stephen Schultz, stephen.schultz@compasspathways.com, +1 401 290 7324
Source: Compass Pathways plc
FAQ
When will Compass Pathways (CMPS) release Q3 2024 earnings?
What time is Compass Pathways (CMPS) Q3 2024 earnings call?
How long will Compass Pathways (CMPS) Q3 2024 earnings webcast be available?
